AstraZeneca's Lynparza fails in combination trial
18th May 2016 07:37
(ShareCast News) - AstraZeneca said on Wednesday that its trial of ovarian cancer drug Lynparza in combination with chemotherapy, compared with paclitaxel hemotherapy alone, did not meet the primary endpoint of overall survival in advanced gastric cancer patients. The drugmaker said while there was
Read moreAstraZeneca asthma drug 'well tolerated' in trials
17th May 2016 07:41
(ShareCast News) - AstraZeneca said Tuesday its potential new asthma treatment benralizumab had shown positive results in a phase III trial. In a statement, the company said benralizumab had been "was well tolerated and achieved the primary endpoint in two pivotal Phase III registrational trials dem
Read moreSunday newspaper round-up: RBS, Shell, Cobham, BT, banks
15th May 2016 17:01
(ShareCast News) - Royal Bank of Scotland is examining a range of radical options to help speed the long-delayed separation and flotation of its Williams & Glyn subsidiary, including a potential divestment of its NatWest brand. Banking sources have indicated to the Sunday Telegraph that RBS and its
Read moreAstraZeneca's selumetinib receives Orphan Drug Designation
12th May 2016 08:01
(ShareCast News) - AstraZeneca was celebrating on Thursday, after the US Food and Drug Administration granted its investigational MEK ½ inhibitor, selumetinib, 'Orphan Drug Designation' for adjuvant treatment of patients with stage III or IV differentiated thyroid cancer. The FTSE 100 company said d
Read moreLondon pre-open: All eyes on BoE's Carney and Vlieghe
12th May 2016 07:24
(ShareCast News) - A cautious tone is expected to prevail at the start of trading, with traders sitting on their hands of the results of today's Monetary Policy Committee meeting, minutes and Inflation Report. Against that backdrop, the Footsie is being called to start the session 27 points beneath
Read moreAstraZeneca, Shell plotting debt sales ahead of ECB corporate QE-programme
9th May 2016 15:31
(ShareCast News) - AstraZeneca was marketing €2.2bn of debt in a three-part of deal, according to people familiar with the deal cited by Bloomberg. Airbus Group and Royal Dutch Shell were also marketing their own bonds, the same people said, with US outfit Bunge and Spanish insurer Mapfre having als
Read moreLondon pre-open: Stocks seen higher on upbeat US cues
3rd May 2016 07:28
(ShareCast News) - London stocks were expected to open in the black on Tuesday, taking their cue from a positive session in the US as traders return to their desks following the long bank holiday weekend. The FTSE 100 was seen opening 28 points higher than Friday's close at 6,270. On the data front
Read moreAstraZeneca completes rights sale on Imdur; closes buy from Takeda Pharma
3rd May 2016 07:06
(ShareCast News) - AstraZeneca said it has completed the divestment of the global rights to angina treatment Imdur, outside the US, to China Medical System Holdings Ltd and its associated company, Tibet Rhodiola Pharmaceutical Holding Co. Under the agreement, AstraZeneca will receive $19 m for the r
Read moreAstraZeneca first-quarter revenue up, earnings down
29th Apr 2016 07:38
(ShareCast News) - AstraZeneca posted a drop in first-quarter earnings but a rise in revenue as core research and development costs increased, reflecting recent acquisitions. Core earnings per share fell 7% at constant currency and 12% in dollar terms to 95 cents, while revenue was up 5% at constant
Read moreFTSE 100 movers: Standard Chartered lifted while AstraZeneca sinks
26th Apr 2016 14:25
(ShareCast News) - The FTSE 100 was treading water on Tuesday afternoon, managing to keep itself in the black in contrast to its sibling index. Emerging markets-exposed bank Standard Chartered was among the top performers, as investors showed their approval of the bank's ongoing turnaround. It poste
Read moreAstraZeneca, Ironwood agree US licensing deal for gout treatment
26th Apr 2016 09:40
(ShareCast News) - AstraZeneca said it had entered a licensing agreement with Ironwood Pharmaceuticals over exclusive US rights to Zurampic, which is used to treat hyperuricemia associated with uncontrolled gout. Ironwood will get rights to Zurampic and exclusive US rights to the fixed-dose combinat
Read moreAstraZeneca's Bevespi Aerosphere approved by US FDA
26th Apr 2016 08:06
(ShareCast News) - AstraZeneca said announced that the US Food and Drug Administration has approved its Bevespi Aerosphere inhalation aerosol for treating patients with chronic obstructive pulmonary disease. Bevespi Aerosphere or glycopyrrolate and formoterol fumarate is used for the long-term, main
Read moreSunday newspaper round-up: AstraZeneca, Monarch Airlines, HSBC, Opec deal
17th Apr 2016 16:53
(ShareCast News) - AstraZeneca has held talks with US-based rival Medivation that could see it make a $10bn (£7bn) takeover bid, where it will battle France's Sanofi, which had a bid rejected last week, and others. Although oncology drug maker Medivation has been criticised for "price gouging" by Am
Read moreBroker tips: Aviva, Diageo, Astrazeneca
12th Apr 2016 12:42
(ShareCast News) - Recent underperformance led analysts at Credit Suisse to remove Aviva from their Europe Focus List, but they expected the stock's price to close the gap versus its peers over the next few years. The decision to remove the stock from that list was triggered by the shares' breach of
Read moreThursday broker round-up
7th Apr 2016 15:32
(ShareCast News) - Zoopla: UBS downgrades to neutral with a target price of 260p. Caledonia Mining: Panmure Gordon downgrades to hold, 61p target. Burberry: RBC downgrades underperform with a target price of 1300p, JP Morgan reiterates neutral with a target of 1400p and UBS keeps at buy with a targ
Read more